Olema Pharmaceuticals, Inc. (OLMA)
| Market Cap | 1.05B +208.9% |
| Revenue (ttm) | n/a |
| Net Income | -185.15M |
| EPS | -2.03 |
| Shares Out | 87.35M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 757,195 |
| Open | 11.93 |
| Previous Close | 11.80 |
| Day's Range | 11.87 - 12.21 |
| 52-Week Range | 4.47 - 36.26 |
| Beta | 2.01 |
| Analysts | Strong Buy |
| Price Target | 40.70 (+237.76%) |
| Earnings Date | Aug 7, 2026 |
About OLMA
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. The company’s lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in seco... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for OLMA stock is "Strong Buy." The 12-month stock price target is $40.7, which is an increase of 237.76% from the latest price.
News
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, developme...
Olema Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The company is advancing two late-stage assets for ER+, HER2- breast cancer, with OPERA-01 phase III data expected in the fall and KAT6 combination data anticipated by year-end. Strong cash reserves support ongoing trials and potential commercialization, while trial designs are being refined based on recent industry data.
Olema Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026
OP-3136 and palazestrant clinical programs are advancing, with promising efficacy and safety data in breast and prostate cancer. Upcoming trial readouts and industry data may drive design changes and strategic decisions, while strong cash reserves support ongoing development.
Olema Pharmaceuticals Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
OP-3136, a selective KAT6/KAT7 inhibitor, shows early efficacy and favorable tolerability in phase I, with ongoing and planned combination trials in breast and prostate cancer. Major phase III readouts are expected in the fall, targeting large market opportunities.
Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer
Study to evaluate OP-3136, Olema's novel KAT6 inhibitor, in combination with darolutamide in approximately 36 patients; expected to initiate in H2 2026 First clinical collaboration for OP-3136; result...
Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting
OP-3136 monotherapy was well-tolerated with no dose-limiting toxicities observed and no discontinuations due to treatment-related adverse events OP-3136 shows evidence of anti-tumor activity across mu...
Olema Oncology to Participate in Upcoming Investor Conferences
SAN FRANCISCO, May 19, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, developmen...
Citi opens ‘upside 90-day catalyst watch’ on Olema Oncology
Citi opened an “upside 90-day catalyst watch” on Olema Oncology (OLMA) while keeping a Buy rating on the shares with a $62 price target The company will present initial clinical…
Olema Oncology price target lowered to $35 from $38 at Guggenheim
Guggenheim lowered the firm’s price target on Olema Oncology (OLMA) to $35 from $38 and keeps a Buy rating on the shares. The firm, which has updated its model for…
Olema Pharmaceuticals Quarterly report: Q1 2026
Olema Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 12, 2026.
Olema Pharmaceuticals Earnings release: Q1 2026
Olema Pharmaceuticals released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Olema Oncology Appoints Prakash Raman, Ph.D., to Board of Directors
SAN FRANCISCO, April 29, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, developm...
Olema Pharmaceuticals Proxy statement: Proxy filing
Olema Pharmaceuticals filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Olema Pharmaceuticals Proxy statement: Proxy filing
Olema Pharmaceuticals filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Olema Oncology to Present Initial Clinical Data for OP-3136 at the 2026 ASCO Annual Meeting
SAN FRANCISCO, April 21, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, developm...
Olema Oncology initiated with a Peer Perform at Wolfe Research
Wolfe Research initiated coverage of Olema Oncology (OLMA) with a Peer Perform rating and no price target Olema is pursuing development in second-line metastatic breast cancer and first-line mBC for…
Olema Oncology assumed with a Buy at Jefferies
Jefferies analyst Dennis Ding assumed coverage of Olema Oncology (OLMA) with a Buy rating and price target of $40, down from $43. The firm views Olema as a “high quality”…
Olema Oncology price target raised to $58 from $55 at JPMorgan
JPMorgan raised the firm’s price target on Olema Oncology (OLMA) to $58 from $55 and keeps an Overweight rating on the shares. The firm updated models in the smid-cap biotechnology…
Olema Oncology price target lowered to $27 from $38 at Goldman Sachs
Goldman Sachs analyst Richard Law lowered the firm’s price target on Olema Oncology (OLMA) to $27 from $38 and keeps a Buy rating on the shares. Olema Oncology reported Q4…
Olema Oncology price target lowered to $38 from $40 at Guggenheim
Guggenheim lowered the firm’s price target on Olema Oncology (OLMA) to $38 from $40 and keeps a Buy rating on the shares. Olema reiterated timelines for the Phase 3 palazestrant…
Olema Oncology price target raised to $62 from $60 at Citi
Citi raised the firm’s price target on Olema Oncology (OLMA) to $62 from $60 and keeps a Buy rating on the shares. The firm sees a favorable risk/reward into the…
Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
On-track to report top-line data in the fall of 2026 from the pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in patients with 2/3L ER+/HER2- metastatic breast cancer Advanced enrollme...
Olema Pharmaceuticals Annual report: Q4 2025
Olema Pharmaceuticals has published its Q4 2025 annual report on March 16, 2026.
Olema Pharmaceuticals Earnings release: Q4 2025
Olema Pharmaceuticals released its Q4 2025 earnings on March 16, 2026, summarizing the period's financial results.
Olema Pharmaceuticals, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – OLMA
LOS ANGELES--(BUSINESS WIRE)--Olema Pharmaceuticals, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – OLMA.